Why lymphoma patients may become resistant to specific therapy

Researchers have discovered a mechanism of drug resistance to Venetoclax®, also known as ABT-199, a BCL-2 targeting drug commonly used to treat chronic lymphocytic leukemia and acute myeloid leukemia. Their findings also suggest a possible co-treatment strategy to overcome this resistance.